Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/pharmaessentia-corp" target="_blank" data-smartkarma-citation="entities:16461:1" rel="noopener">Pharmaessentia Corp (6446 TT)</a> received FDA approval for its rare cancer drug, BESREMi, which has superior clinical efficacy over the existing standard of care.</li>
<li>The drug has already been approved in 17 countries in EU, Taiwan, and South Korea. It is also being developed for several other indications, with license expected in next year.</li>
<li>BESREMi’s continued success in the EU markets since its launch in 2019 has enhanced my conviction on the commercial accomplishment of BESREMi in the U.S.</li>
</ul>



Pharmaessentia Corp (6446 TT) received FDA approval for its rare cancer drug, BESREMi, which has superior clinical efficacy over the existing standard of care.
The drug has already been approved in 17 countries in EU, Taiwan, and South Korea. It is also being developed for several other indications, with license expected in next year.
BESREMi’s continued success in the EU markets since its launch in 2019 has enhanced my conviction on the commercial accomplishment of BESREMi in the U.S.


Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow

Taiwan

PharmaEssentia Corporation develops and distributes therapeutic products for treatment in human disease. The Company develops drugs to treat hepatitis, chronic myeloid leukemia (CML), essential thrombocythemia (ET), myeloid fibrosis (MF), polycythemia vera (PV), hepatitis and cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pharmaessentia Corp (6446 TT): First In-House Drug Approval in the U.S., More to Follow

Pharmaessentia received FDA approval for its new biologics drug for a rare cancer. This article has analyzed its superiority over the existing...

Tina Banerjee